Login / Signup

Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study.

Daniele Assad SuzukiAlessandra Menezes MorelleMayana Lopes de BritoFlavia Rocha PaesAndré MattarJorge H Santos LealSérgio Daniel SimonEllias Magalhães Abreu LimaGustavo WerutskyGustavo H Munhoz PiottoJose BinesLucas Petri DamianiAriane Vieira Scarlatelli MacedoLígia CamposAnna Maria Buehler
Published in: JCO global oncology (2024)
The high-quality evidence from the BrasiLEEira study corroborates the RCTs' findings, expanding its validity to a broader spectrum and underrepresented population who may benefit from ribociclib treatment.
Keyphrases
  • young adults
  • combination therapy